|
C9ORF21 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.27620136680662E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.1712966414309E-11 |
| Normal-vs-Stage2 |
2.73459999089454E-09 |
| Normal-vs-Stage3 |
6.10023143110539E-12 |
| Normal-vs-Stage4 |
1.71718195218773E-12 |
| Stage1-vs-Stage2 |
6.020400E-01 |
| Stage1-vs-Stage3 |
2.105400E-01 |
| Stage1-vs-Stage4 |
6.360100E-03 |
| Stage2-vs-Stage3 |
2.144600E-01 |
| Stage2-vs-Stage4 |
1.042260E-02 |
| Stage3-vs-Stage4 |
1.002760E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.06750164263758E-11 |
| Normal-vs-AfricanAmerican |
3.16460000004959E-06 |
| Normal-vs-Asian |
9.49760048385428E-10 |
| Caucasian-vs-AfricanAmerican |
8.518800E-01 |
| Caucasian-vs-Asian |
6.230800E-01 |
| AfricanAmerican-vs-Asian |
9.315600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.06480388342811E-11 |
| Normal-vs-Female |
1.72859504488088E-11 |
| Male-vs-Female |
8.539800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.76619871242679E-11 |
| Normal-vs-Age(41-60Yrs) |
6.08291195192123E-12 |
| Normal-vs-Age(61-80Yrs) |
5.79991610294428E-12 |
| Normal-vs-Age(81-100Yrs) |
9.679500E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.463800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.232800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.005400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.528600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.653400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.279400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.286400E-02 |
| Classical-VS-Follicular |
2.181800E-01 |
| Classical-VS-Other |
9.691000E-01 |
| Classical-VS-Normal |
4.03039823737572E-11 |
| Tall-VS-Follicular |
6.763400E-03 |
| Tall-VS-Other |
2.511200E-01 |
| Tall-VS-Normal |
8.56315018893383E-13 |
| Follicular-VS-Other |
7.326400E-01 |
| Follicular-VS-Normal |
2.08429995485204E-09 |
| Other-VS-Normal |
9.78259999999676E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.38069555788434E-11 |
| Normal-vs-N1 |
1.92512672470002E-12 |
| N0-vs-N1 |
4.826100E-02 |
|
|
